Meeting
2020 ASCO Virtual Scientific Program
Association of lymphocyte to monocyte ratio with clinical response and survival in patients with relapsed, aggressive non-Hodgkin lymphoma treated with axicabtagene ciloleucel CAR-T.
Authors
Abdullah S. Al Saleh
Mayo Clinic, Rochester, MN
Abdullah S. Al Saleh , Sangeetha Gandhi , Tuan Truong , Arushi Khurana , Eva Brandes , Breanna Estby , Gina Lange , Stephen M. Ansell , N. Nora Bennani , Patrick B. Johnston , Jonas Paludo , Jose Caetano Villasboas , Luis F. Porrata , Yi Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3028)
DOI
10.1200/JCO.2020.38.15_suppl.3028
Abstract #
3028
Poster Bd #
92
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.
First Author: Radhika Bansal
Poster
2023 ASCO Annual Meeting
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
First Author: Laura S. Samples
Poster
2022 ASCO Annual Meeting
CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.
First Author: Sarah Marie Larson
Poster
2021 ASCO Annual Meeting
Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.
First Author: Henan Zhang